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S U M M A R Y
Introduction: Boceprevir (BOC) was one of the ﬁrst oral inhibitors of hepatitis C virus (HCV) NS3 protease
to be developed. This study assessed the safety and efﬁcacy of BOC + pegylated interferon-a2a/ribavirin
(PEG-IFN/RBV) in the retreatment of HIV–HCV co-infected patients with HCV genotype 1.
Methods: This was a phase III prospective trial. HIV–HCV (genotype 1) co-infected patients from
16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed
by response-guided therapy with PEG-IFN/RBV plus BOC (a ﬁxed 44 weeks was indicated in the case of
cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-
treatment. Efﬁcacy and safety were evaluated in all patients who received at least one dose of the study
drug.
Results: From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one
treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had
genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-
responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients
(78%) completed the therapy scheme; the most common reasons for discontinuation were lack of
response at week 12 (12 patients) and adverse events (six patients).
Conclusions: Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR
rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well
tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe
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nc-nd/4.0/).1. Introduction
Liver disease caused by chronic hepatitis C virus (HCV) infection
is a leading cause of morbidity and mortality among HIV-infected
patients in the developed world and represents an important
health care problem in this population.1,2 HCV genotype 1 is the
most prevalent in this population.
The standard treatment for HCV infection until 2009 was
the combination of pegylated interferon plus ribavirin
(PEG-IFN/RBV) for 48 weeks. However, the sustained virological
response (SVR) rate achieved in patients with genotype 1 is
low with this combination, at less than 40%.3–6 More than half of
the patients fail to respond and these patients require
retreatment.
In recent years, several drugs with direct antiviral activity
against HCV have been developed (direct-acting antivirals,
DAAs). The ﬁrst DAAs used in combination therapy with PEG-
IFN/RBV were the protease inhibitors of HCV NS3 telaprevir and
boceprevir (BOC). The results of clinical trials with triple therapy
in both monoinfected7,8 and HIV co-infected patients9–11 have
been good. However, data on the efﬁcacy of this regimen in
patients who have not responded to previous PEG-IFN/RBV
therapy are scarce.12–17
Although triple therapy achieves higher rates of SVR than
conventional therapies, it may be more toxic and is clearly more
expensive. There are data indicating that response-guided therapy
(RGT) (32 weeks of triple therapy) in HCV monoinfected patients
with previous failure to PEG-IFN/RBV therapy can be as effective as
the standard triple therapy (44 weeks), but with lower toxicity and
cost.14
Some studies have evaluated the efﬁcacy and safety of triple
therapy with protease inhibitors in HIV–HCV co-infected patients
previously treated with PEG-IFN/RBV,18,19 and one has evaluated
RGT.20
This phase III study assessed the safety and efﬁcacy of RGT with
BOC + PEG-IFN/RBV in the retreatment of HIV–HCV genotype
1 patients who were non-responders or relapsers to PEG-IFN/RBV
therapy.Figure 1. Study design (HCV-VL, viral load of hepatitis C virus; PR, pegylated i2. Methods
2.1. Study design and participating centers
The study was a phase III, prospective, multicenter, open-label,
single-arm trial performed in the specialized HIV units of
16 hospitals of Spain. The study was conducted in accordance
with the principles of Good Clinical Practice. The institutional ethics
committee of Hospital Clinic of Barcelona (coordinating center) and
AEMPS (La Agencia Espan˜ola de Medicamentos y Productos
Sanitarios; Spanish drug agency) approved the study, having taken
into account the opinions of the other Clinical research ethics
committees involved in the project (16 hospitals in Spain). All
patients provided written informed consent before entering the
study. The clinical trial is registered in EudraCT (number 2012-
003984-23). The study design is illustrated in Figure 1.
2.2. Patients
HIV–HCV co-infected patients who had received medical care for
their HIV infection at any of the hospitals participating in the study
were enrolled from June 2013 to April 2014. The patients had to
fulﬁll the following inclusion criteria: previous non-responders or
relapsers to PEG-IFN/RBV therapy; HIV infection with a CD4 cell
count >100 cells/mm3 and undetectable plasma HIV viral load (<50
copies/ml) for more than 6 months; the antiretroviral treatment
had to contain raltegravir (at least during the last 6 weeks).
Cirrhosis was deﬁned by a liver biopsy showing F4 liver ﬁbrosis,
or transient elastography showing a liver stiffness of >12.5 kPa.
Exclusion criteria included the following: hepatitis B virus (HBV)
infection or any other cause of clinically signiﬁcant liver disease,
decompensated liver disease, a severe psychiatric disorder, and
active substance abuse.
2.3. Treatment and monitoring
Pegylated interferon-a2a was administered subcutaneously at
a dose of 180 mg once weekly. Ribavirin was administered twice anterferon plus ribavirin; TW8, therapy week 8; TW12, therapy week 12).
*patients w ith detec table HCV RNA at week 12  of therapy had to discont inue all 
therapy (futil ity rule est abl ished in the protocol) 
102 patients enrol led
98 patients treated 
(96% of enroll ed patients)
2 Failure  of inclus ion cri teria
2 Withdr awals d id not start ed the 
study
76 patients  completed 
the therapy
(78% of included pati ent s)
12 Trea tment f ailure  (Futility rule)*
2 Patient de cis ions
6 Advers e events r elated  to stu dy drugs 
1 Hepato cellula r carcin oma
1 Lost to follow up
Figure 2. Flow chart. *Patients with detectable HCV RNA at week 12 of therapy had
to discontinue all therapy (futility rule established in the protocol).
M. Laguno et al. / International Journal of Infectious Diseases 53 (2016) 46–5148day at a dose of 800 to 1200 mg per day on the basis of body weight.
Boceprevir was administered at a dose of 800 mg three times daily.
During the 4-week lead-in period, all patients received PEG-IFN/
RBV. Subsequent treatment varied according to the degree of liver
ﬁbrosis and viral response at this point: (1) patients with an HCV
RNA decrease of <1 log10 and all patients with cirrhosis received
BOC + PEG-IFN/RBV for 44 weeks; (2) patients who achieved a 1
log10 drop in HCV RNA received a RGT regimen consisting of (a)
BOC + PEG-IFN/RBV for 32 weeks if the HCV RNA level was
undetectable at weeks 8 and 12 (completed therapy at week 36);
(b) PEG-IFN/RBV for an additional 12 weeks if the HCV RNA level
was detectable at week 8 (but undetectable at week 12) (Figure 1) .
In all groups, failure to achieve an undetectable HCV RNA level
at week 12 resulted in discontinuation of all treatments and
advancement to follow-up. Plasma HCV RNA levels were measured
using the VERSANT HCV RNA 1.0 Assay (kPCR) (Siemens
Healthcare), which has a lower limit of quantiﬁcation and
detection of 15 IU/ml. Measurements were performed at the
baseline visit, weeks 4, 8, 12, 24, 36, and 48, as well as at weeks
12 and 24 of the follow-up period.
2.4. Assessment of efﬁcacy
The primary measure of efﬁcacy was the SVR rate, deﬁned as the
proportion of patients with undetectable HCV RNA in serum at the
end of follow-up (24 weeks after cessation of treatment), by an
intent-to-treat (ITT) analysis of the whole population and also
according to baseline characteristics. Possible predictors of SVR
were also analyzed.
2.5. Assessment of safety
Adverse events were graded according to a modiﬁcation of the
World Health Organization scale. Therapy was permanently
discontinued in patients who developed life-threatening events.
In the case of hematological toxicity, the RBV or PEG-IFN dose was
lowered according to the drug label recommendations, and full
doses were restarted, if possible, when the hematological
parameters had returned to previously normal levels for that
patient. The use of granulocyte colony-stimulating factor (G-CSF)
and erythropoietin was permitted in this study and used at the
discretion of the physician responsible for each patient.
2.6. Statistical analysis
Analyses of the primary outcome (SVR) included data from all
patients who received at least one dose of any study medication.
Other efﬁcacy analyses included the proportion of patients with an
early response (i.e., undetectable HCV RNA level at weeks 4 and 8)
in those who achieved SVR and the proportion of patients with a
relapse.
The proportion of patients with SVR was expressed as a
percentage with the 95% conﬁdence interval (CI). Quantitative
characteristics were described using the mean and standard
deviation (SD) or median and interquartile range (IQR) and
compared between groups with the t-test and Wilcoxon rank
sum test, respectively. Qualitative variables were described using
the absolute frequency and percentage and were compared
between groups with the Chi-square test or Fisher’s exact test.
Logistic regression models were used to identify baseline factors
inﬂuencing SVR. Characteristics were chosen on the basis of
clinical judgment and statistical criteria (simple regression model
p-value <0.1) and were evaluated in a stepwise fashion. All tests
were two-tailed with the signiﬁcance level set at 5%. The statistical
software used for the analyses was Stata Release 13 (StataCorp LP,
College Station, TX, USA).3. Results
3.1. Baseline characteristics
A total of 102 patients were included in the study, of whom
98 received at least one treatment dose and were included in the
analysis (Figure 2). The baseline demographic characteristics are
shown in Table 1. The mean age of the patients was 49 years; 100%
of the patients were Caucasian and 73% were male.
The prevalence of infection with HCV genotypes 1a and 1b was
65% and 35%, respectively. Polymorphism IL28B CC was present in
23% of patients. A total of 34% of patients had cirrhosis.
Most patients were non-responders to previous HCV therapy:
41% were null responders and 23% were partial responders. One
third of patients included were relapsers.
In accordance with the inclusion criteria of the study, all
patients had an undetectable HIV viral load and a high CD4 cell
count (median 674, IQR 510–946 cells/mm3).
Following the study design, patients were divided into three
therapy groups: 48 patients (67% with cirrhosis) entered the long
arm (BOC + PEG-IFN/RBV for 48 weeks) and 50 patients entered the
RGT arm; the treatment duration could be shortened to 36 weeks
in 12 of these latter patients.
3.2. Efﬁcacy
The global SVR rate was 67% (95% CI 57–76%). In particular, the
SVR rate was 85% among patients with prior relapse and 57%
among those with a previous null response. In cirrhotic patients,
the SVR rate dropped to 51% (Table 2).
When an analysis was done by treatment arm, the SVR rate was
48% with the long treatment, 92% with the short RGT, and 84% in
the group receiving long RGT.
Viral breakthrough occurred in only four patients. HCV relapsed
during follow-up in 10 patients (13% of patients with HCV negative
at the end of therapy); in three cases the relapse was delayed,
occurring between weeks 12 and 24 of follow-up. Nine relapses
occurred in the group of patients assigned to the ﬁxed long arm
therapy.
Sixty-nine patients (70%) had a good response to PEG-IFN/RBV,
deﬁned as a decrease in HCV RNA of 1 1og10 IU/ml after the
Table 1
Baseline characteristicsa
Variable Summary
statistics
Age, years 49 (SD 6)
Sex Male 72 (73%)
Female 26 (27%)
Total 98 (100%)
IL28 CC 21 (23%)
CT 65 (70%)
TT 7 (8%)
Total 93 (100%)
HCV viral load IU/ml 2 291 335 (758 209–4 303 728)
HCV genotype 1a 61 (65%)
1b 33 (35%)
Total 94 (100%)
Previous response to
HCV therapy
Breakthrough 6 (7%)
Relapse 27 (30%)
Null response 37 (41%)
Partial response 21 (23%)
Total 91 (100%)
Degree of liver ﬁbrosis F1 36 (38%)
F2 11 (11%)
F3 16 (17%)
F4 33 (34%)
Total 96 (100%)
% CD4 37.65 (29–999.9)
CD4 count, cells/mm3 674 (510–946)
HIV viral load 25 (19–37)
IL28, interleukin 28; HCV, hepatitis C virus.
a Results are reported as the arithmetic mean (standard deviation, SD), number
(column percentage), or median (interquartile range).
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worse (20 patients; 61%).
The decrease of 1 log HCV RNA at week 4 was associated with a
higher rate of SVR; nevertheless, those patients who did not show a
decrease of 1 log HCV RNA during this period had a very low SVR
rate (17%). The positive predictive value (PPV) of achieving SVR in
the group of patients with a response at 4 weeks was 84%; the PPV
was lower in cirrhotic patients (70%).
Similarly, the 8-week response (decrease 2 log or HCV RNA
undetectable at week 8 of therapy) was related to SVR; 66% ofTable 2
Sustained virological response (SVR) rate according to baseline characteristics and
HCV RNA evolution during treatment
Variable SVR, n (%) p-Value
Sex Male 47 (65) 0.4673a
Female 19 (73)
IL28 CC 14 (67) 0.1291b
CT 45 (69)
TT 2 (28)
HCV genotype 1a 40 (65) 0.4776a
1b 24 (72)
Previous response to PEG-IFN/RBV
therapy
Breakthrough 5 (83) 0.0842b
Relapse 23 (85)
Partial response 14 (66)
Null response 21 (57)
Previous null response No 42 (73) 0.0328a
Yes 21 (57)
Cirrhosis No 48 (76) 0.0141b
Yes 18 (51)
Response at 4 weeks (HCV RNA
decrease 1 log)
No 10 (17) <0.0001a
Yes 56 (81)
Response at 8 weeks (HCV RNA
undetectable or decrease 2 log)
No 0 (0) 0.0002b
Yes 66 (72)
Early response (HCV RNA undetectable
at weeks 8 and 12)
No 56 (64) 0.0964b
Yes 10 (91)
IL28, interleukin 28; HCV, hepatitis C virus; PEG-IFN/RBV, pegylated interferon/
ribavirin.
a Chi-square test.
b Fisher’s exact test.patients who had this response achieved SVR (PPV 73%). Of most
importance at this point is the negative predictive value (100%); no
patient without a response at 8 weeks achieved SVR.
The simple logistic regression analysis identiﬁed three factors
that were signiﬁcantly associated with the achievement of SVR:
previous response to PEG-IFN/RBV therapy (no null response vs.
null response), 4-week response, and absence of cirrhosis. In this
study, no positive relationship was found between SVR and sex,
IL28b, or genotype 1 subtype (Table 3).
In the multiple model, the following factors remained
independently associated with SVR: a good response at 4 weeks
(vs. not presenting such a response, odds ratio (OR) 9.50, 95% CI
3.12–28.95; p = 0.0001) and the absence of cirrhosis (vs. cirrhosis,
OR 3.22, 95% CI 1.05–9.89; p = 0.0407).
3.3. Safety
Seventy-six patients completed the assigned treatment sched-
ule. Twelve patients discontinued treatment at week 12 of therapy
due to the futility rule established in the protocol; this represents
55% of patients who prematurely stopped the therapy. The second
reason for ending the study drugs was toxicity (six patients). Two
other patients discontinued at weeks 8 and 12 of their own
volition. One patient stopped after receiving a diagnosis of
metastatic hepatocellular carcinoma and one patient was lost at
week 36 of follow-up.
Adverse events (AEs) were very frequent; 93% of patients
presented at least one AE, but the mean was seven AEs per patient.
Most AEs were mild and known to be related to PEG-IFN/RBV and
BOC therapy (ﬂu-like symptoms, asthenia, neuropsychiatric
symptoms, hematological toxicity, dysgeusia, and rash).
Due to hematological toxicity, the dose of RBV was decreased in
45% of patients and the dose of PEG-IFN was decreased in 23% of
patients. No difference in the SVR rate was seen between patients
who completed the whole therapy and those who needed a dose
modiﬁcation. Overall, 20% of patients required treatment with
erythropoietin and 14% with G-CSF; two patients received
transfusions. Regarding the degree of liver ﬁbrosis, no more AEs
were observed in cirrhotic patients; however, the need to reduce
the dose of PEG-IFN and to use erythropoietin or drugs to treat
dermatological toxicities was signiﬁcantly greater in these
patients.
Twenty-seven serious AEs (SAEs) were reported in 19 patients;
these led to therapy discontinuation in six patients. The most
frequent SAEs were hematological (thrombocytopenia, n = 5;
neutropenia, n = 8; anemia, n = 3). SAEs were most frequent in
patients with cirrhosis (30% vs. 13%, p = 0.0358).
4. Discussion
This appears to be the ﬁrst phase III trial with BOC in HIV–HCV
co-infected patients. The results of this study showed that RGT
with BOC plus PEG-IFN/RBV achieved high rates of SVR in patients
with a prior treatment failure. This was most evident in patients
who had previously relapsed or had a breakthrough to PEG-IFN/
RBV, who showed a SVR rate of up to 80%. On the other hand, the
response was moderate in previously null responders. These
results are in line with those reported in recent studies on the
retreatment of HCV monoinfected patients,14 and in series in co-
infected patients.18
Data on RGT to re-treat HCV in HIV co-infected patients are
scarce. A recent study in 21 patients showed good results with this
strategy,20 although most of the patients were treatment-naı¨ve
(71%) and no prior partial or null responders were included in that
study, unlike the present one.
Table 3
Variables related to a sustained virological response (SVR)
Variable Crude OR (95% CI) p-Value (simple model) Adjusted OR (95% CI) p-Value (multiple model)
Sex
(n = 83)
Female 1 0.9138
Male 0.94 (0.33–2.68)
IL28
(n = 79)
CC 1 0.2235
CT 1.22 (0.39–3.81)
TT 0.25 (0.04–1.77)
HCV genotype
(n = 80)
1a 1 0.7226
1b 1.20 (0.44–3.28)
Cirrhosis
(n = 83)
No 2.19 (1.38–3.49) 0.0106 3.22 (1.05–9.89) 0.0407
Yes 1 1
Previous null response
(n = 83)
No 1 0.0266
Yes 0.34 (0.13–0.88)
Early response
(n = 83)
No 1 0.1964
Yes 4.08 (0.48–34.48)
Response at 4 weeks
(n = 83)
No 1 <0.0001 1 0.0001
Yes 10.07 (3.43–29.57) 9.50 (3.12–28.95)
Response at 8 weeks
(n = 78)
No 1 -
Yes 1.00 -
OR, odds ratio; CI, conﬁdence interval; IL28, interleukin 28; HCV, hepatitis C virus.
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response was the best marker to determine the likelihood of
SVR. Also, the lack of an 8-week response identiﬁed patients who
did not beneﬁt from this treatment, and allowed therapy
discontinuation at this point. If the predictive value of this marker
is conﬁrmed in other studies, it could eventually change the futility
rule from12 weeks to 8 weeks.
It is important to emphasize that only one patient relapsed in
the short arm of RGT, showing that a shortened treatment duration
in patients with a good initial response is safe and effective.
Patients with advanced liver disease, who usually have a mild
response,23–25 also achieved a satisfactory rate of SVR.
Although the safety proﬁle was poor and a high number of AEs
were reported, all of them have been described previous-
ly,7,14,16,23,26 most were mild, and only six patients discontinued
treatment for this reason. Cirrhotic patients did not report more
AEs or interruptions of therapy compared to non-cirrhotic patients
in this study, unlike those published by other authors.24,25
However, cirrhotic patients in the present study had more SAEs
and required more drug dose modiﬁcations and use of adjuvant
therapy. Therefore, these patients should be followed closely to
complete the therapy scheme and achieve a good response.
By trial design, SVR was determined at 24 weeks after the end of
therapy. In fact three patients relapsed after 12 weeks of follow-up,
which shows that according to this approach, the determination of
SVR at 24 weeks may be more useful than at 12 weeks.
The most important limitation of this study is the lack of a
control group. Phase III studies are often randomized with a group
receiving the standard treatment; however, very difﬁcult to treat
HIV–HCV co-infected patients were included, for whom treatment
options are limited. In this population, the use of a control group
would have been difﬁcult to justify from an ethical point of view
because response rates to the PEG-IFN/RBV scheme are low.
Finally, it is agreed that with the advent of interferon-free therapy ,
the treatment regimen evaluated herein has been rendered
obsolete. However, these newer drugs are not available for all
patients. Based on the high efﬁcacy obtained in this study,
especially in prior relapsers, it is believed that the scheme of RGT
with BOC + PEG-IFN/RBV is a good therapeutic and cost-effective
alternative in countries where new antiviral HCV drugs are not
available.
In conclusion, response-guided therapy with boceprevir in
combination with PEG-IFN/RBV leads to adequate SVR rates in HCV
genotype 1 patients who are previous non-responders or relapsers
to PEG-IFN/RBV therapy. The therapy was generally well tolerated.Acknowledgements
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